Sun, L., Tran, N., Liang, C., et al.Design, synthesis, and evalutaions of substituted 3-[(3- or 4-carboxyethylpyrrol-2-yl)methylidenyl]indolin-2-ones as inhibitors of VEGF, FGF, and PDGF receptor tyrosine kinasesJ. Med. Chem.42(25),5120-5130(1999)

Kammasud, N., Boonyarat, C., Sanphanya, K., et al.5-Substituted pyrido[2,3-d]pyrimidine, an inhibitor against three receptor tyrosine kinasesBioorg. Med. Chem. Lett.19(3),745-750(2009)

Laird, A.D., Vajkoczy, P., Shawver, L.K., et al.SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumorsCancer Res.60(15),4152-4160(2000)

Griffin, R.J., Williams, B.W., Wild, R., et al.Simultaneous inhibition of the receptor kinase activity of vascular endothelial, fibroblast, and platelet-derived growth factors suppresses tumor growth and enhances tumor radiation responseCancer Res.62(6),1702-1706(2002)

Laird, A.D., Christensen, J.G., Li, G., et al.SU6668 inhibits Flk-1/KDR and PDGFRβ in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in miceFASEB J.16(7),681-690(2002)

Gangjee, A., Kurup, S., Ihnat, M.A., et al.Synthesis and biological activity of N4-phenylsubstituted-6-(2,4-dichloro phenylmethyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamines as vascular endothelial growth factor receptor-2 inhibitors and antiangiogenic and antitumor agentsBioorg. Med. Chem.18(10),3575-3587(2010)

Godl, K., Gruss, O.J., Eickhoff, J., et al.Proteomic characterization of the angiogenesis inhibitor SU6668 reveals multiple impacts on cellular kinase signalingCancer Res.65(15),6919-6926(2005)

Bain, J., Plater, L., Elliot, M., et al.The selectivity of protein kinase inhibitors: A further updateBiochem. J.408(3),297-315(2007)